Cancer is the 2nd major cause of human morbidity and mortality. Consequently, PhD and MD/PhD researchers trained in Cancer Biology and professionally involved in cancer research are a critical national health need. It is our view that a truly interdisciplinary graduate curriculum with a major focus upon the biology of cancer that interfaces with clinicians engaged in cancer diagnosis and treatment provides an excellent means of training specialists with a sufficient breadth of perspective for a successful independent career in cancer research. This is an application for renewal of a training grant currently in its 20th year to support 6 pre-doctoral candidates principally from the Graduate Program in Cancer Biology (GPCB) at the Wayne State University (WSU) and the Karmanos Cancer Institute (KCI). Trainees will include both PhD and MD/PhD candidates and are selected from our diverse candidate population, including underrepresented minorities. Training draws from the outstanding clinical and research facilities at WSU/KCI and the expertise of 17 training faculty in areas ranging from fundamental processes involved in neoplastic development, invasion and metastasis, to cancer therapy and prevention. A cornerstone of our training environment is the GPCB, comprised of over 50 faculty from academic and clinical departments throughout our university, that provides a unique educational environment through extended cancer courses, lectures, seminars and symposia that culminates in a PhD in Cancer Biology. Graduate students will have the opportunity to become familiar with state-of-the-art methods in molecular and cell biology and will receive clinical exposure to the cancer problem through """"""""rounding"""""""" with oncologists at the KCI Cancer Hospital and attendance at KCI Grand Rounds. Training of the most outstanding graduate candidates from the GPCB will be significantly enhanced by a 2 year appointment to this NCI-sponsored training grant. The training experience for the T32 trainees will enable each to pursue a successful career in cancer research. During the past 20 years, this T32 CA009351 grant has trained an impressive group of cancer biologists who are currently contributing to basic scientific and translational cancer research efforts at research institutes throughout the United States. In accomplishing this, the training program has significantly contributed to meeting the critical national need for domestic and US-trained PhDs with a long term career commitment to cancer related research.

Agency
National Institute of Health (NIH)
Institute
National Cancer Institute (NCI)
Type
Institutional National Research Service Award (T32)
Project #
5T32CA009531-25
Application #
8134751
Study Section
Special Emphasis Panel (ZCA1-RTRB-A (M1))
Program Officer
Damico, Mark W
Project Start
1985-09-01
Project End
2012-08-31
Budget Start
2011-09-01
Budget End
2012-08-31
Support Year
25
Fiscal Year
2011
Total Cost
$138,843
Indirect Cost
Name
Wayne State University
Department
Pharmacology
Type
Schools of Medicine
DUNS #
001962224
City
Detroit
State
MI
Country
United States
Zip Code
48202
McFall, Thomas; McKnight, Brooke; Rosati, Rayna et al. (2018) Progesterone receptor A promotes invasiveness and metastasis of luminal breast cancer by suppressing regulation of critical microRNAs by estrogen. J Biol Chem 293:1163-1177
Shah, Seema; Brock, Ethan J; Jackson, Ryan M et al. (2018) Downregulation of Rap1Gap: A Switch from DCIS to Invasive Breast Carcinoma via ERK/MAPK Activation. Neoplasia 20:951-963
Jones, Steven K; Douglas, Kirk; Shields, Anthony F et al. (2018) Correlating quantitative tumor accumulation and gene knockdown using SPECT/CT and bioluminescence imaging within an orthotopic ovarian cancer model. Biomaterials 178:183-192
Guastella, Anthony R; Michelhaugh, Sharon K; Klinger, Neil V et al. (2018) Investigation of the aryl hydrocarbon receptor and the intrinsic tumoral component of the kynurenine pathway of tryptophan metabolism in primary brain tumors. J Neurooncol 139:239-249
Saadat, Nadia; Liu, Fangchao; Haynes, Brittany et al. (2018) Nano-delivery of RAD6/Translesion Synthesis Inhibitor SMI#9 for Triple-negative Breast Cancer Therapy. Mol Cancer Ther 17:2586-2597
Heyza, Joshua; Lei, Wen; Watza, Donovan et al. (2018) Identification and characterization of synthetic viability with ERCC1 deficiency in response to interstrand crosslinks in lung cancer. Clin Cancer Res :
Ravindra, Manasa; Wilson, Mike R; Tong, Nian et al. (2018) Fluorine-Substituted Pyrrolo[2,3- d]Pyrimidine Analogues with Tumor Targeting via Cellular Uptake by Folate Receptor ? and the Proton-Coupled Folate Transporter and Inhibition of de Novo Purine Nucleotide Biosynthesis. J Med Chem 61:4228-4248
McKnight, Brooke N; Viola-Villegas, Nerissa T (2018) 89 Zr-ImmunoPET companion diagnostics and their impact in clinical drug development. J Labelled Comp Radiopharm 61:727-738
Herroon, Mackenzie K; Rajagurubandara, Erandi; Diedrich, Jonathan D et al. (2018) Adipocyte-activated oxidative and ER stress pathways promote tumor survival in bone via upregulation of Heme Oxygenase 1 and Survivin. Sci Rep 8:40
Blocker, Stephanie J; Shields, Anthony F (2018) Imaging of Nanoparticle Distribution to Assess Treatments That Alter Delivery. Mol Imaging Biol 20:340-351

Showing the most recent 10 out of 164 publications